Reed Joshua
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Scholar Rock Refiles Apitegromab Application With EMA. Scholar Rock has resubmitted its marketing authorization application to the European Medicines Agency for apitegromab, a treatment for spinal muscular atrophy in children and adults. This regulatory step follows the company's recent release of its Q2 2026 financial results. The stock is currently trading near its 52-week low, which provides context for the significance of this regulatory update.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Biotech Sector News Dominates; No Specific ALDX Updates. Recent news coverage focuses on clinical trial results for other biotechnology companies, such as ACAD and Vertex, rather than Aldeyra Therapeutics. There are no new company-specific announcements or trial updates for ALDX in the provided reports. The stock is currently trading near its 52-week low, reflecting broader sector sentiment rather than isolated corporate news.
Transaction History
| ALKS | ▲ Buy | Option Exercise | 9,164 | — | 10/8/2026 | View on chart |
| ALKS | ▼ Sell | Tax Withholding | 4,069 | $163K | 10/8/2026 | View on chart |
| SRRK | ▼ Sell | Open Market | 2,105 | $113K | 7/1/2026 | View on chart |
| SRRK | ▼ Sell | Open Market | 948 | $51K | 7/1/2026 | View on chart |
| SRRK | ▲ Buy | Grant | 6,839 | $0 | 6/4/2026 | View on chart |
| SRRK | ▼ Sell | Open Market | 4,900 | $145K | 5/29/2025 | View on chart |
| SRRK | ▼ Sell | Open Market | 500 | $15K | 5/29/2025 | View on chart |
| SRRK | ▲ Buy | Grant | 7,632 | $0 | 5/22/2025 | View on chart |
| SRRK | ▲ Buy | Grant | 13,500 | $0 | 6/27/2024 | View on chart |
| ALDX | ▲ Buy | Grant | 93,322 | $0 | 3/30/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Baird Highlights Growth Potential for Alkermes plc (ALKS)
Baird has highlighted Alkermes plc as a company with promising growth potential, citing its pipeline and recent developments. A Yahoo article compares Alkermes to LQDA, discussing which biotech may be more attractive for investors. The stock is currently trading near its 200‑day moving average and close to a key support level of $48.74, while analysts average a target of $56.56.
Baird Highlights Growth Potential for Alkermes plc (ALKS). Baird has highlighted Alkermes plc as a company with promising growth potential, citing its pipeline and recent developments. A Yahoo article compares Alkermes to LQDA, discussing which biotech may be more attractive for investors. The stock is currently trading near its 200‑day moving average and close to a key support level of $48.74, while analysts average a target of $56.56.